Moreover preclinical findings showed that enzalutamide inhibits the growth of HER2 breast cancer cells, suggesting that the activity of AR inhibition might be anticipated in HER2 tumors, even independently of HER2 inhibition [43]. Here, AR is linked to breast cancer.